| Dr Maria L Parayno, MD | |
|
1500 Duarte Rd, Duarte, CA 91010-3012 | |
| (626) 256-4673 | |
| Not Available |
| Full Name | Dr Maria L Parayno |
|---|---|
| Gender | Female |
| Speciality | Nuclear Medicine |
| Experience | 18 Years |
| Location | 1500 Duarte Rd, Duarte, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336387505 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| City Of Hope Medical Foundation | 3779751656 | 686 |
News Archive
Carol Berkowitz, MD, and Mallory D. Witt, MD, lead researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, received the Serge & Yvette Dadone Clinical Teaching Award in Honor of Saleh Salehmoghaddam, M.D., a peer-reviewed recognition of their "outstanding dedication, innovation, and sustained excellence in clinical and classroom teaching," according to the David Geffen School of Medicine at UCLA, which presented the awards.
The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.
The 1918 influenza pandemic provides a cautionary tale for what the future may hold for COVID-19, says a Michigan State University researcher.
Hot on the heels of discovering a protective form of immune response to spinal cord injury, researchers at the University of Virginia School of Medicine have pinpointed the biological trigger for that response - a vital step toward being able to harness the body's defenses to improve treatment for spine injuries, brain trauma, Alzheimer's disease and other neurodegenerative conditions.
› Verified 5 days ago
| Entity Name | City Of Hope Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871886366 PECOS PAC ID: 3779751656 Enrollment ID: O20110720000244 |
News Archive
Carol Berkowitz, MD, and Mallory D. Witt, MD, lead researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, received the Serge & Yvette Dadone Clinical Teaching Award in Honor of Saleh Salehmoghaddam, M.D., a peer-reviewed recognition of their "outstanding dedication, innovation, and sustained excellence in clinical and classroom teaching," according to the David Geffen School of Medicine at UCLA, which presented the awards.
The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.
The 1918 influenza pandemic provides a cautionary tale for what the future may hold for COVID-19, says a Michigan State University researcher.
Hot on the heels of discovering a protective form of immune response to spinal cord injury, researchers at the University of Virginia School of Medicine have pinpointed the biological trigger for that response - a vital step toward being able to harness the body's defenses to improve treatment for spine injuries, brain trauma, Alzheimer's disease and other neurodegenerative conditions.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maria L Parayno, MD Po Box 512185, Los Angeles, CA 90051-0185 Ph: () - | Dr Maria L Parayno, MD 1500 Duarte Rd, Duarte, CA 91010-3012 Ph: (626) 256-4673 |
News Archive
Carol Berkowitz, MD, and Mallory D. Witt, MD, lead researchers at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, received the Serge & Yvette Dadone Clinical Teaching Award in Honor of Saleh Salehmoghaddam, M.D., a peer-reviewed recognition of their "outstanding dedication, innovation, and sustained excellence in clinical and classroom teaching," according to the David Geffen School of Medicine at UCLA, which presented the awards.
The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.
The 1918 influenza pandemic provides a cautionary tale for what the future may hold for COVID-19, says a Michigan State University researcher.
Hot on the heels of discovering a protective form of immune response to spinal cord injury, researchers at the University of Virginia School of Medicine have pinpointed the biological trigger for that response - a vital step toward being able to harness the body's defenses to improve treatment for spine injuries, brain trauma, Alzheimer's disease and other neurodegenerative conditions.
› Verified 5 days ago